Showing posts with label Roper. Show all posts
Showing posts with label Roper. Show all posts

Sunday, August 8, 2021

Roper Looking Stronger As The Recovery Broadens And Deepens

 

In my last article on Roper Technologies (ROP) I commented that Roper isn't really a company geared for early short-cycle recoveries, but that as the recovery matured sentiment would recover. And so it has been, with the shares outperforming the broader industrial space since that last article, rising about 15% against a flattish performance for the sector.

Valuation isn't any simpler now, though. Roper has been a free cash flow machine for two decades, generating close to 20% cash flow growth over the last 20 years and over 10% growth over the last decade, driving annualized returns of close to 20% a year over both of those periods.

If you believe that 10%-plus FCF growth can be sustained, the shares still offer a worthwhile return, and Roper should be seeing improving demand across a wide range of its businesses. That long-term growth is going to require ongoing M&A activity (a quality issue for some investors), though, and you have to go through some contortions to find the shares cheap on a multiple-based methodology today.


Read the full article here: 

Roper Looking Stronger As The Recovery Broadens And Deepens

Tuesday, April 13, 2021

Roper Has Underperformed Recently, But The Valuation Argument Isn't Clear-Cut

 

One of the tricky things about investing in companies where the valuation has decoupled from the underlying financial reality is that sentiment can shift without much reason, and you really don’t know when it will come back.

There are definitely some issues with Roper (ROP) and some valid bear arguments, but the underperformance since my last article (about 36% relative to the broader industrial sector) has surprised me, even though I did think the shares were overvalued.

Whether this is a “buy the dip” opportunity really depends on your confidence in the business model. If Roper can maintain double-digit growth, the shares do seem to offer a FCF-based prospective return on par with other high-quality industrials. If growth is more likely to be in the mid-to-high single-digits, though, the valuation isn’t nearly so appealing. On top of that, Roper isn’t particularly well-leveraged to where we are in the cycle, nor to some of the more favored industrial themes right now.

 

Click here to continue: 

Roper Has Underperformed Recently, But The Valuation Argument Isn't Clear-Cut

Friday, January 3, 2020

Roper's Share Price Has Flattened, While The Compounder Model Hums Along

To paraphrase a long-time reader, it's worth asking if Roper (NYSE:ROP) is more wily or Wile E. Coyote - is this M&A-driven decentralized growth model truly something special (and something sustainable), or has valuation run off the cliff with nothing left to support it other than the fact investors haven't yet looked down?

Valuation is never an exact process, but I do think Roper is more the former (a special company/model) than the latter (a sentiment-driven future train wreck). Roper doesn't buy growth so much as it buys market share, moats, and margins (three M's, that 3M (MMM) would do well to copy in its M&A strategy), and the company's decentralized model gives it a range of potential targets that is far wider than almost any of its peers. What's more, the company is increasingly software-centric, given its asset-light model with high recurring revenue and less cyclicality. I'm not suddenly reversing course and declaring Roper a bargain, but I do at least see why investors value this company as they do.

Click here for more:
Roper's Share Price Has Flattened, While The Compounder Model Hums Along

Sunday, May 5, 2019

Ongoing Excellence And Premium Valuation Mean Loving IDEX From Afar

Playing a "I like it, but the shares are expensive" drinking game with my articles in the industrial sector would probably be lethal right now, but the fact remains that the market continues to reward many companies with robust valuations even though there are some pockets of weakness in short-cycle markets. IDEX (IEX) is one of my favorite companies, a disciplined deployer of capital with strong niche-based businesses and excellent margins, but it's hard to see how IDEX shares can keep generating attractive returns from this high level.

Read the full article here:
Ongoing Excellence And Premium Valuation Mean Loving IDEX From Afar

Tuesday, April 30, 2019

Roper's Growth Engine Keeps Humming

As a multi-industrial increasingly driven by its high-margin, asset-light software businesses, Roper (ROP) continues to diverge from the broader multi-industrial category in generally positive ways. Management has built a solid value-compounding engine here, and Wall Street is quite well aware of that, with the shares up another 30%-plus over the trailing twelve months. I do expect Roper to continue to deliver better-than-average organic growth with improving margins, and I believe Roper has a repeatable formula here for successful M&A, it’s increasingly difficult for me to see value in the shares. Yes, there are investors in companies like Roper and Danaher (DHR) that will argue for buying irrespective of valuation, but that’s not my approach and I think shareholders should at least be aware of the risks if Roper’s engine ever has a hiccup along the way.

Read more here:
Roper's Growth Engine Keeps Humming

Tuesday, February 26, 2019

Roper Getting Its Due As A Differentiated Value-Creator

Exclude valuation from the conversation, and I’m not sure how many negatives you can really come up with for Roper (ROP). Not only has Roper shown that it can identify, execute, and integrate acquisitions just as well as peers like Danaher (DHR) but management has used M&A to transform the business into a self-funding, niche-focused, asset-light multi-industrial with a very strong recurring revenue component driven by a diverse SaaS and medical/healthcare business. Although the ROIC is lower than you might otherwise expect, that doesn’t trouble me much given the strong demonstrated cash flow generation ability.

Roper isn’t cheap by any approach I use, but I do like the company’s end-market exposures and business model for this point in the cycle, as well as the “dry powder” the company has to make further value-enhancing acquisitions. And while the shares aren’t cheap, they’re not too far from my DCF-based fair value and this would be a very tempting name on another market sell-off.

Click here for more:
Roper Getting Its Due As A Differentiated Value-Creator

Wednesday, August 29, 2018

An Unexpected Leadership Transition Likely Won't Faze Roper

It’s hard to find much to pick at with Roper (ROP). Sure, the ROIC/CROCI could be a little higher, but this tech and software-driven multi-industrial has “out-Danaher’ed” Danaher (DHR) over the past 15 years with a 20% annualized return driven by well above-average revenue growth, operating margins, FCF growth, and FCF margins. What’s more, the company’s transition toward niche-based, asset-light, SaaS-driven recurring revenue puts the company in a sweet spot with respect to many of its more cyclical peers.

Roper investors got a negative surprise on Friday, though, as the company announced that Neil Hunn would be assuming the CEO position effective on September 1, with Brian Jellison stepping down. While this transition is coming about three years sooner than expected, Hunn has been groomed for this position for some time. Rising valuations and ample capital left to deploy will test Hunn early in his tenure, but my basic viewpoint today is that Jellison established a model that can continue to generate strong results without him.

Read more here:
An Unexpected Leadership Transition Likely Won't Faze Roper

Thursday, June 14, 2018

Fortive Following A Familiar Pattern

If you're well-acquainted with Danaher (DHR) and Roper (ROP), Fortive's (FTV) strategy is going to look pretty familiar in at least some respects. Like both Danaher and Roper, Fortive's management doesn't want to be the classic sort of industrial conglomerate and is instead pivoting towards more technology-driven markets, and particularly those with higher service/recurring revenue components. It's no surprise, of course, that Fortive would be similar to Danaher (from which it was spun out), and the company has yet to really follow Roper's SaaS focus, but in any case, Fortive management is not afraid to pay big multiples for businesses that it believes will generate attractive long-term margin profiles.

As far as the shares go, I'm not inclined to chase them here. The stock already seems to factor in healthy future cash flow growth, and I'm not willing to count on significant further expansion in short-term multiples for the industry.

Read the full article here:
Fortive Following A Familiar Pattern

Monday, April 30, 2018

Roper Technologies Comes Through Again

Investors continue to appreciate Roper’s (ROP) M&A-driven growth and its leverage to higher-margin product categories like SaaS (including medical software), metering, and controls/instrumentation. Although industrial conglomerates on the whole haven’t had an especially good run since the fourth-quarter earnings reporting season, Roper has continued to outperform both the market and many of its peers. With good underlying market drivers, strong cash flow, and upcoming M&A deployments, the underlying drivers for Roper still look to be very much in place.

Continue here:
Roper Technologies Comes Through Again

Danaher's Growing Leverage To Life Sciences Improves The Long-Term Outlook

As investors have become a little more concerned that the industrial recovery story has peaked, Danaher's (DHR) far larger skew towards health and life sciences has started looking better and better. At the risk of oversimplification, I think the greater skew toward health care/life sciences can partly explain why Danaher and Roper (ROP) have outperformed peers like 3M (MMM), Honeywell (HON), and Illinois Tool Works (ITW) over the last three months (although industrial-heavy Fortive (FTV) has led the group, so it's not a flawless hypothesis…).

Danaher doesn't look especially cheap, but that's been the norm for much of the company's history and it hasn't prevented the company from outperforming the S&P 500, as management continues to apply a proven successful model. With greater exposure toward long-term growth opportunities like diagnostics and bioproduction, I like Danaher's mix even if the valuation is not scintillating.

Read more here:
Danaher's Growing Leverage To Life Sciences Improves The Long-Term Outlook

Sunday, April 1, 2018

Fortive Accelerating Its Transformation Process

Fortive (NYSE:FTV) management had already made it clear to shareholders that they wanted services and software to be a bigger part of the future, but the pace of that transformation has been a little surprising. Between the recent transaction with Altra (NASDAQ:AIMC) and the prospect of $8 billion in M&A deployment, Fortive is certain to look different in 2020. Although this transformation carries unknowns and risks, including the extent to which the Fortive Business System is “portable” into these new target areas, the success of peers like Roper (NYSE:ROP) argues that it could be a very worthwhile shift.

Read the full article here:
Fortive Accelerating Its Transformation Process

Sunday, March 4, 2018

Is It Too Late For An Early-Cycle Name Like Parker Hannifin?

Investors have an uncanny knack for swinging between worrying about nothing and worrying about everything. In the case of Parker-Hannifin (PH), it would seem that poorly-communicated, near-term margin issues are disappointing investors who favor margin improvement stories within the multi-industrial space, while worries about where Parker-Hannifin sits in the short-/mid-/late-cycle ecosystem are troubling other investors.

Although I do have some concerns about growth with Parker-Hannifin, I think the stock's valuation is interesting on both an absolute and relative basis, particularly given acceleration in orders and high valuations in the peer group. To me, the shares look priced for high-single-digit to low-double-digit total returns, and you could make an argument that a fair value in the $220s or $230s wouldn't be ridiculous.

Read the full article:
Is It Too Late For An Early-Cycle Name Like Parker Hannifin?

For Roper, More Of The Same Looks Like A Good Plan

What do you say about a company that has averaged a total annual return to shareholders of over 20% the last 15 years, has outgrown its multi-industrial peer group on organic revenue, and generates FCF margins in the 20%’s while shifting the model towards more recovering revenue? All I can really say about Roper Technologies (ROP) is that this is definitely a stock to keep in mind when the music stops and the market cools off.

I discussed the challenges of valuing a stock like Roper the last time I wrote about the company (in which time the stock has risen another 30%), and it’s no easier now. Including the company’s near-term M&A plans into the valuation would suggest a mid-to-high single-digit total annual return is still in play, and I would also note that Roper’s valuation relative to other multi-industrials like Danaher (DHR), Honeywell (HON), Illinois Tool Works (ITW), and 3M (MMM) hasn’t really changed all that much compared to a trailing multiyear average.

Click here for more:
For Roper, More Of The Same Looks Like A Good Plan

Sunday, May 7, 2017

Roper Technologies Delivering Good Core Growth As Markets Turn

When I last wrote about Roper (NYSE:ROP), I wasn't totally sold on the valuation given some concerns I had about the business outside of energy and I thought it was a name to reconsider on a pullback into/around earnings. The shares cooperated, pulling back about 5% before a trifecta of good news (the U.S. Presidential election, the Deltek acquisition, and stronger results/orders in the fourth quarter) really stoked up the enthusiasm for these shares.

I've compared Roper to Danaher (NYSE:DHR) before, and I'll do it again - like Danaher, Roper can be a difficult stock for more value-oriented investors, as Wall Street loves the company's growth model and margins and will pay a premium for that growth. That seems particularly true now in a recovery environment where Roper not only seems poised to produce solid growth in absolute terms, but also on a relative basis.

Although Roper doesn't look like a bargain in discounted cash flow model, dropping the discount rate by just 1% gives me a fair value in line with the price today and a high single-digit expected return isn't bad, particularly for a company with good leverage to an emerging oil/gas recovery. Therein lies one of the issues with modeling and price target calculation - a modest change to an assumption or two can swing the result significantly. So while I still can't call Roper a bargain, the growth potential and strong cash flow generation capabilities leave it as a name still worth considering for more aggressive portfolios.

Read more here:
Roper Technologies Delivering Good Core Growth As Markets Turn

Wednesday, April 30, 2014

Seeking Alpha: Roper Delivers A Best-In-Class Performance

Conditions seem to have improved in a big way for industrial conglomerate Roper (ROP) in a relatively short time. Not only did Roper beat expectations for the quarter, but the company delivered one of the best results in its sector. Roper is seldom an exceptionally cheap stock, but valuation isn't too demanding and the combination of good order momentum and an active hunt for M&A could lead to a more active 2014 for shareholders.

Follow the link to read more:
Roper Delivers A Best-In-Class Performance

Tuesday, May 14, 2013

Investopedia: Roper A LIttle Short On Growth, But A Proven Builder Of Value

As much as investors and analysts talk about growth, you'd think that would be the be-all end-all of stock selection. The data tells a different story, though, particularly in the industrial sector. When it comes to industrials, at least the diversified conglomerates, it would seem that margin leverage, improving ROICs, and active capital deployment are what really drive shares over the long term. To that end, Roper (NYSE:ROP) still looks like an interesting stock to watch.
Another Unimpressive Growth Story
The theme for the first quarter of 2013 has been disappointing and dreary industrial earnings reports, and Roper certainly fits that theme. While reported revenue rose 4%, organic revenue was down 3% on an identical decline in volume. That puts Roper behind other conglomerates like ABB (NYSE:ABB) and Danaher (NYSE:DHR), ahead of GE (NYSE:GE) and Illinois Tool Works (NYSE:ITW), and in basically the same boat as companies like Dover (NYSE:DOV) and Honeywell (NYSE:HON).
Please follow the link to continue:
http://www.investopedia.com/stock-analysis/051413/roper-little-short-growth-proven-builder-value-rop-dhr-ge-itw-hon.aspx

Tuesday, March 12, 2013

Seeking Alpha: Measurement Specialties Doesn't Quite Measure Up

Measurement Specialties (MEAS) is hardly a household name for most investors, as it barely has any sell-side coverage. Even so, the institutions which own nearly 90% of the shares haven't let the stock go unrewarded - like so many other industrial stocks, these shares are close to their 52-week high despite pretty unspectacular near-term expectations. While Measurement Specialties should have ample opportunity to grow its business through customized sensor offerings and increased per-product sensor content, the valuation already seems to incorporate generous growth in the coming years.

Please click here to continue:
Measurement Specialties Doesn't Quite Measure Up